BiondVax Pharmaceuticals Ltd. (BVXV) News
Filter BVXV News Items
BVXV News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BVXV News Highlights
- For BVXV, its 30 day story count is now at 6.
- Over the past 18 days, the trend for BVXV's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about BVXV are DRUG, LUNG and PARA.
Latest BVXV News From Around the Web
Below are the latest news stories about BIONDVAX PHARMACEUTICALS LTD that investors may wish to consider to help them evaluate BVXV as an investment opportunity.
BiondVax Touts Additional Preclinical Data From Inhaled COVID-19 Treatment CandidateBiondVax Pharmaceuticals Ltd (NYSE: BVXV) announced additional results in a preclinical proof-of-concept study of its innovative inhaled NanoAb COVID-19 drug. The study compared weight loss in two groups of hamsters. Hamsters administered a mid-sized 0.66mg dose of the NanoAb three hours before infection experienced no significant weight loss over the six-day trial. But the untreated control group's weight declined 12% on average, a highly statistically significant difference. The prophylactic r |
BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo StudyCOVID-19 illness was virtually prevented in hamsters administered BiondVax’s inhaled NanoAb and infected three hours later with SARS-CoV-2 Data further strengthens value proposition of BiondVax’s COVID-19 NanoAb as prophylactic and therapeutic drug; Previously announced data indicated NanoAb treatment one day post infection led to significantly milder illness, faster recovery, and lower viral lung titer in comparison to the placebo groupFirst-in-human Phase 1/2a clinical trial is planned for 202 |
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Receives $57 Share Valuation on Potential of NanoAb PlatformCalendar year 2022 has been eventful for BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases. Recently, the company was covered in a recent research report by Zacks Small-Cap Research (https://nnw.fm/JPc5L). The report valued the company at $57.00 … Continue reading "BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Receives $57 Share Valuation on Potential of NanoAb Platform" The post BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Receives $57 Share Valuation on Potential of NanoAb Platform appeared first on NetworkNewsWire . |
BiondVax''s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo StudyHamsters infected with SARS-COV-2 and then treated with BiondVax''s inhaled anti-COVID-19 nanosized antibodies (NanoAbs) had over 30-times lower lung viral titer on average compared to those treated with inhaled placebo Result builds on recently announced data indicating NanoAb treatment led to significantly milder illness and faster recovery in comparison to the placebo group BiondVax''s NanoAbs are being formulated as a convenient self‑administered inhaled drug for treatment and potential prophylactic prevention of COVID-19 First-in-human Phase 1/2a clinical trial planned for 2023 The COVID-19 therapy is BiondVax''s first in a new pipeline of innovative alpaca-derived NanoAb therapies addressing diseases with large underserved medical needs and attractive commercial opportunities such... |
BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo StudyHamsters infected with SARS-COV-2 and then treated with BiondVax’s inhaled anti-COVID-19 nanosized antibodies (NanoAbs) had over 30-times lower lung viral titer on average compared to those treated with inhaled placeboResult builds on recently announced data indicating NanoAb treatment led to significantly milder illness and faster recovery in comparison to the placebo groupBiondVax’s NanoAbs are being formulated as a convenient self‑administered inhaled drug for treatment and potential prophyla |
BiondVax to Present at Biotech Showcase 2023JERUSALEM, Jan. 05, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced today that Mr. Amir Reichman, BiondVax’s CEO will present at the Biotech Showcase conference being held Jan. 9-11, 2023. The Biotech Showcase Conference is taking place in San Francisco in para |
BiondVax CEO Issues Letter to ShareholdersJERUSALEM, Dec. 30, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products for the treatment of infectious and autoimmune diseases, today published a letter from its CEO, Amir Reichman, addressing 2022 accomplishments, successful preclinical trial results of the inhaled COVID-19 NanoAb therapy as well as recent financing activities to support 2 |
Aegis Capital Corp. Acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV)Aegis Capital Corp. acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV). |
BiondVax Announces Closing of $8 Million Underwritten Public OfferingJERUSALEM, Dec. 20, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV)(“Company”), a biotechnology company, which focuses on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced the closing of its underwritten public offering with gross proceeds to the Company to be $8,000,000, before deducting underwriting discounts and other expenses payable b |
BeyondSpring, Exact Sciences top healthcare gainers; Synaptogenix, BiondVax among losersBeyondSpring (BYSI) +46%. Exact Sciences (EXAS) +24%. Synaptogenix (SNPX) -69%. BiondVax Pharmaceuticals BVXV -57%. |